Two drugs received accelerated approval for IgA nephropathy: one has met its confirmatory endpoint, the other is moving ahead despite miss

Idorsia’s aprocitentan under review, while Mineralys and AZ prepare for Phase III trials and Alnylam runs two more Phase II studies

Drug development for heart failure is picking up, with five clinical readouts from five mechansims expected in the next year